Published in Lancet on September 13, 2003
Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis (2009) 4.19
Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res (2005) 4.00
HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev (2011) 3.28
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol (2007) 3.18
A replication clock for Mycobacterium tuberculosis. Nat Med (2009) 2.49
Patterns of delays amongst pulmonary tuberculosis patients in Lagos, Nigeria. BMC Public Health (2004) 2.46
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS One (2006) 2.18
NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog (2005) 2.04
Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog (2011) 1.99
Treatment outcome of tuberculosis patients at Gondar University Teaching Hospital, Northwest Ethiopia. A five--year retrospective study. BMC Public Health (2009) 1.95
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med (2006) 1.90
Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother (2007) 1.78
Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev (2015) 1.76
Has the DOTS strategy improved case finding or treatment success? An empirical assessment. PLoS One (2008) 1.74
Silencing Mycobacterium smegmatis by using tetracycline repressors. J Bacteriol (2007) 1.66
Molecular diagnostics in tuberculosis. Eur J Clin Microbiol Infect Dis (2005) 1.55
Tuberculosis as a risk factor for systemic lupus erythematosus: results of a nationwide study in Taiwan. Rheumatol Int (2011) 1.52
Differences in critical care practice between an industrialized and a developing country. Wien Klin Wochenschr (2008) 1.52
Mycobacterium tuberculosis produces pili during human infection. Proc Natl Acad Sci U S A (2007) 1.50
An autosomal dominant major gene confers predisposition to pulmonary tuberculosis in adults. J Exp Med (2006) 1.48
Promoter variation in the DC-SIGN-encoding gene CD209 is associated with tuberculosis. PLoS Med (2006) 1.42
Mycobacterial bacilli are metabolically active during chronic tuberculosis in murine lungs: insights from genome-wide transcriptional profiling. J Bacteriol (2007) 1.40
Regulation of the Mycobacterium tuberculosis mce1 operon. J Bacteriol (2006) 1.37
Mycolic acid modification by the mmaA4 gene of M. tuberculosis modulates IL-12 production. PLoS Pathog (2008) 1.30
Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol (2010) 1.29
Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis. Pulm Med (2012) 1.24
Tuberculosis due to resistant Haarlem strain, Tunisia. Emerg Infect Dis (2005) 1.24
Study of tuberculosis and AIDS stigma as barriers to tuberculosis treatment adherence using validated stigma scales. Int J Tuberc Lung Dis (2011) 1.21
Nucleotide-binding oligomerization domain protein 2-deficient mice control infection with Mycobacterium tuberculosis. Infect Immun (2007) 1.21
Modeling the Mycobacterium tuberculosis Granuloma - the Critical Battlefield in Host Immunity and Disease. Front Immunol (2013) 1.21
Prospects for clinical application of electronic-nose technology to early detection of Mycobacterium tuberculosis in culture and sputum. J Clin Microbiol (2006) 1.20
Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice. Clin Exp Immunol (2005) 1.18
Demonstration of components of antigen 85 complex in cerebrospinal fluid of tuberculous meningitis patients. Clin Diagn Lab Immunol (2005) 1.17
Phosphorylation of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis. J Biol Chem (2010) 1.15
CD209 genetic polymorphism and tuberculosis disease. PLoS One (2008) 1.14
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother (2008) 1.14
Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis (2008) 1.14
Costs of a successful public-private partnership for TB control in an urban setting in Nepal. BMC Public Health (2007) 1.13
P2X7 and NRAMP1/SLC11 A1 gene polymorphisms in Mexican mestizo patients with pulmonary tuberculosis. Clin Exp Immunol (2007) 1.11
Tuberculosis chemotherapy: current drug delivery approaches. Respir Res (2006) 1.11
Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am J Respir Crit Care Med (2012) 1.08
Role for lysosomal enzyme beta-hexosaminidase in the control of mycobacteria infection. Proc Natl Acad Sci U S A (2008) 1.08
Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis. PLoS One (2013) 1.07
Isolation of nontuberculous mycobacteria in Zambia: eight case reports. J Clin Microbiol (2005) 1.06
Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS One (2013) 1.05
Tuberculosis drug resistance and HIV infection, the Netherlands. Emerg Infect Dis (2007) 1.04
Macrophages in tuberculosis: friend or foe. Semin Immunopathol (2013) 1.04
Increasing adherence to inhaled steroid therapy among schoolchildren: randomized, controlled trial of school-based supervised asthma therapy. Pediatrics (2009) 1.04
From Corynebacterium glutamicum to Mycobacterium tuberculosis--towards transfers of gene regulatory networks and integrated data analyses with MycoRegNet. Nucleic Acids Res (2009) 1.04
Resequencing and association analysis of the SP110 gene in adult pulmonary tuberculosis. Hum Genet (2006) 1.03
Imaging of tuberculosis of the abdominal viscera: beyond the intestines. J Clin Imaging Sci (2013) 1.02
Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis. PLoS One (2011) 1.02
TB, or not TB: that is the question -- does TLR signaling hold the answer? J Clin Invest (2004) 1.01
Use of hydrogen peroxide vapor for deactivation of Mycobacterium tuberculosis in a biological safety cabinet and a room. J Clin Microbiol (2006) 0.98
Co-infection with human immunodeficiency virus and tuberculosis in Asia. Tuberculosis (Edinb) (2007) 0.98
Epidemiological profile of adult patients with tuberculosis and AIDS in the state of Espírito Santo, Brazil: cross-referencing tuberculosis and AIDS databases. J Bras Pneumol (2011) 0.98
Community-based DOTS and family member DOTS for TB control in Nepal: costs and cost-effectiveness. Cost Eff Resour Alloc (2008) 0.97
Prevalence of tuberculous lymphadenitis in Gondar University Hospital, Northwest Ethiopia. BMC Public Health (2013) 0.97
In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol (2004) 0.97
Strain diversity of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Afar pastoral region of Ethiopia. Biomed Res Int (2014) 0.95
Three-year longitudinal study of genotypes of Mycobacterium tuberculosis isolates in Tuscany, Italy. J Clin Microbiol (2007) 0.95
Characterization of Mycobacterium tuberculosis Beijing isolates from the Mediterranean area. BMC Microbiol (2010) 0.95
Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis. J Infect Dis (2013) 0.95
The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. Int J Tuberc Lung Dis (2008) 0.93
Bioaerosol mass spectrometry for rapid detection of individual airborne Mycobacterium tuberculosis H37Ra particles. Appl Environ Microbiol (2005) 0.92
Species spectrum of nontuberculous mycobacteria isolated from clinical specimens in Kuwait. Curr Microbiol (2008) 0.92
Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis. Infect Immun (2005) 0.92
Hepatotoxic effects of therapies for tuberculosis. Nat Rev Gastroenterol Hepatol (2010) 0.92
Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine. Immunology (2006) 0.92
New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res (2010) 0.92
Plasma antibody profiles as diagnostic biomarkers for tuberculosis. Clin Vaccine Immunol (2011) 0.91
Association of IFNGR2 gene polymorphisms with pulmonary tuberculosis among the Vietnamese. Hum Genet (2011) 0.91
Characteristics of suppressor macrophages induced by mycobacterial and protozoal infections in relation to alternatively activated M2 macrophages. Clin Dev Immunol (2012) 0.90
QSAR study of some 5-methyl/trifluoromethoxy- 1H-indole-2,3-dione-3-thiosemicarbazone derivatives as anti-tubercular agents. Res Pharm Sci (2009) 0.90
Application of optical imaging to study of extrapulmonary spread by tuberculosis. Tuberculosis (Edinb) (2009) 0.89
High mortality during tuberculosis treatment does not indicate long diagnostic delays in Vietnam: a cohort study. BMC Public Health (2007) 0.89
Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared. Clin Rheumatol (2007) 0.88
Characterization of Mce4A protein of Mycobacterium tuberculosis: role in invasion and survival. BMC Microbiol (2008) 0.88
Assembly and proteolytic processing of mycobacterial ClpP1 and ClpP2. BMC Biochem (2011) 0.88
Fibrinogen regulates the cytotoxicity of mycobacterial trehalose dimycolate but is not required for cell recruitment, cytokine response, or control of mycobacterial infection. Infect Immun (2009) 0.88
Interleukin 12B (IL12B) genetic variation and pulmonary tuberculosis: a study of cohorts from The Gambia, Guinea-Bissau, United States and Argentina. PLoS One (2011) 0.88
Trends in tuberculosis mortality in the United States, 1990-2006: a population-based case-control study. Public Health Rep (2010) 0.87
Analysis of immune responses against a wide range of Mycobacterium tuberculosis antigens in patients with active pulmonary tuberculosis. Clin Vaccine Immunol (2012) 0.87
Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front Cell Infect Microbiol (2012) 0.87
Extraspinal tuberculous arthritis in HIV era. Clin Rheumatol (2006) 0.86
Forkhead-associated (FHA) domain containing ABC transporter Rv1747 is positively regulated by Ser/Thr phosphorylation in Mycobacterium tuberculosis. J Biol Chem (2011) 0.85
Validation of biomarkers for distinguishing Mycobacterium tuberculosis from non-tuberculous mycobacteria using gas chromatography-mass spectrometry and chemometrics. PLoS One (2013) 0.85
Coexistence of pancreatic carcinoma and pancreatic tuberculosis: case report. Gut Liver (2011) 0.85
Wax ester synthesis is required for Mycobacterium tuberculosis to enter in vitro dormancy. PLoS One (2012) 0.85
Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One (2013) 0.84
Should interventions to reduce respirable pollutants be linked to tuberculosis control programmes? BMJ (2004) 0.84
Effect of multidrug resistance on global tuberculosis control. Lancet (2003) 0.84
Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda. BMC Infect Dis (2015) 0.84
Diagnosis and treatment of latent tuberculosis infection. Tuberc Respir Dis (Seoul) (2015) 0.84
The clinical utility of tuberculin skin test and interferon-γ release assay in the diagnosis of active tuberculosis among young adults: a prospective observational study. BMC Infect Dis (2011) 0.84
Mycobacterium tuberculosis DosR regulon gene Rv0079 encodes a putative, 'dormancy associated translation inhibitor (DATIN)'. PLoS One (2012) 0.83
Tuberculosis Biomarker Extraction and Isothermal Amplification in an Integrated Diagnostic Device. PLoS One (2015) 0.83
Permutations of time and place in tuberculosis. Lancet Infect Dis (2015) 0.83
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med (2014) 28.65
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med (2003) 24.99
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis (2002) 6.73
The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med (2006) 6.53
Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med (2009) 5.93
Global incidence of multidrug-resistant tuberculosis. J Infect Dis (2006) 5.42
Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA (2005) 5.39
The international Ebola emergency. N Engl J Med (2014) 5.35
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
Monitoring mosquito net coverage for malaria control in Africa: possession vs. use by children under 5 years. Trop Med Int Health (2003) 4.29
Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis (2003) 4.10
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature (2006) 3.72
Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet (2002) 3.67
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis (2007) 3.36
Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health (2008) 3.32
Diabetes and the risk of tuberculosis: a neglected threat to public health? Chronic Illn (2007) 3.31
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
West African Ebola epidemic after one year--slowing but not yet under control. N Engl J Med (2014) 2.96
Performance of nucleic acid amplification tests for diagnosis of tuberculosis in a large urban setting. Clin Infect Dis (2009) 2.95
Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science (2003) 2.83
HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis (2006) 2.82
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A (2009) 2.78
Worldwide incidence of malaria in 2009: estimates, time trends, and a critique of methods. PLoS Med (2011) 2.74
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis (2002) 2.68
Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr (2007) 2.53
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ (2005) 2.50
Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis (2003) 2.49
Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis (2006) 2.48
Tuberculosis control in the era of HIV. Nat Rev Immunol (2005) 2.40
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis (2002) 2.33
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol (2009) 2.20
Ebola virus disease in the Democratic Republic of Congo. N Engl J Med (2014) 2.19
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med (2009) 2.18
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Ebola virus disease among children in West Africa. N Engl J Med (2015) 2.17
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16
Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS (2003) 2.11
Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health (2005) 2.09
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis (2009) 2.04
Latent TB infection treatment acceptance and completion in the United States and Canada. Chest (2009) 1.97
Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis (2002) 1.97
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Spatial analysis of tuberculosis cases in migrants and permanent residents, Beijing, 2000-2006. Emerg Infect Dis (2008) 1.91
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis (2005) 1.81
Evaluation of immigrant tuberculosis screening in industrialized countries. Emerg Infect Dis (2012) 1.81
Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med (2007) 1.78
HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med (2012) 1.76
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis (2009) 1.72
What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis (Edinb) (2003) 1.72
Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin Infect Dis (2008) 1.72
Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin Infect Dis (2007) 1.69
Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007. BMC Infect Dis (2010) 1.67
Ebola vaccine--an urgent international priority. N Engl J Med (2014) 1.66
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis (2005) 1.63
Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. Chest (2004) 1.63
Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis (2003) 1.63
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis (2003) 1.53
Low access to a highly effective therapy: a challenge for international tuberculosis control. Bull World Health Organ (2002) 1.53
Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc (2010) 1.51
The development and impact of tuberculosis vaccines. Cell (2006) 1.50
Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A (2010) 1.48
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42
The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med (2003) 1.37
Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis (2004) 1.36
Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol (2005) 1.34
Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review. PLoS One (2009) 1.31
Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother (2010) 1.31
Black race, sex, and extrapulmonary tuberculosis risk: an observational study. BMC Infect Dis (2010) 1.29
The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ (2012) 1.27
Universal genotyping in tuberculosis control program, New York City, 2001-2003. Emerg Infect Dis (2006) 1.25
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med (2002) 1.23
Controlling the last known cluster of Ebola virus disease - Liberia, January-February 2015. MMWR Morb Mortal Wkly Rep (2015) 1.22
Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis (2006) 1.21
Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother (2009) 1.19
Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr (2011) 1.19
Health in financial crises: economic recession and tuberculosis in Central and Eastern Europe. J R Soc Interface (2010) 1.19
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis (2006) 1.18
An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Clin Infect Dis (2011) 1.16
Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One (2013) 1.16